Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosmanogepix - Basilea Pharmaceutica

Next Previous
Drug Profile

Fosmanogepix - Basilea Pharmaceutica

Alternative Names: APX-001; E-1211; E-210; PF-07842805

Latest Information Update: 23 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Amplyx Pharmaceuticals
  • Class Aminopyridines; Antifungals; Antineoplastics; Oxazoles; Phosphates; Small molecules
  • Mechanism of Action GWT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryptococcosis; Coccidioidomycosis; Candidiasis; Aspergillosis; Mycoses
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Candidaemia
  • Phase II Aspergillosis
  • No development reported Acute myeloid leukaemia; Coccidioidomycosis; Mycoses

Most Recent Events

  • 16 Apr 2025 Efficacy and safety data from an expanded access programme in Invasive fungal infections released by Basilea Pharmaceutica
  • 14 Apr 2025 Basilea Pharmaceutica and Biomedical Advanced Research and Development Authority initiates enrolment in a phase I trial for Healthy volunteers in China (PO, IV) (NCT06961708)
  • 13 Apr 2025 Basilea Pharmaceutica plans a phase III trial for invasive mold infections in unknown location (IV, Infusion, PO, Tablet) June 2025 (NCT06925321)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top